Migraine represents today the crossroads of several scientific evidences, such as lofty planetary prevalence, serious disability, damaged quality of life, reduced productive capacity, costly healthcare resulting in a creeping sentiment of social stigma [1–3]. From the same crossroads, the migraine paradigm as a multimorbid disease flows out [4]: perhaps multi-systemic, however to be scanned and evaluated at a distance as the horizon, in order to avoid the risk of parcelling its real extent.
From before the triptans era, in less than 30 years we have passed from the common acceptance of migraine as an ineluctable family heredity to the evidence of a complex genetic trait involving genomics, metabolomics and, perhaps in the near future, also proteomics [5, 6].
In the meantime, the awareness of migraine as real disease has been widespread in the general population and even physicians’ education on migraine has made giant steps forward at different levels of research, professionalism and safe prescription [7–10].
Now that we are facing a new era, the Calcitonin Gene Related Peptide (CGRP) one, with new perspectives and hopes that only a new pharmacological class dedicated to the prevention of migraine can offer, we must not forget what has made this possible: solid and undisputable scientific evidences acquired over the years first on animal and then on human models [11, 12].
This topical collection helps us to orient the readership in the great mass of data that emerge from literature and systematize them in a series of comprehensive reviews, progressively centered on chained topics. From the classic burden of disease to the new acquisitions of genetics, from the new pathophysiology CGRP-centered of migraine to the description of the various new molecules and their correct and safe therapeutic application, up to the rocks of refractoriness and the unavoidable ethical and economic need to identify the right patient for the right drug using the precision medicine [13, 14].
Satisfied all the parameters, before the end of this path we could have the chance to mark out the vanishing point of migraine and to score the greatest try to be devoted to each migraine patient.
Acknowledgements
The article-processing charge has been covered by an educational grant provided by Eli Lilly.
The APCs (article processing charges) for the articles in this thematic series ‘The Changing faces of migraine’ were made possible through independent educational sponsorship by Eli Lilly. Eli Lilly provided the funds through an educational grant which included enduring materials within the context of a symposium at the 12th European Headache Federation Congress in September 2018, chaired by Paolo Martelletti. This grant was provided to Springer Healthcare IME who organized the symposium and all of the enduring materials. Three of the articles in this thematic series were developed from content presented at the symposium. Eli Lilly were not involved in the planning of the thematic series, the selection process for topics, nor in any peer review or decision-making processes.
The articles have undergone the journal’s standard peer review process overseen by the Editor-in-Chief. For articles where the Editor-in-Chief is an author, the peer review process was overseen by one of the other Editors responsible for this thematic series.
Availability of data and materials
Not applicable
Authors’ contributions
All the Authors contributed equally to the preparation of this Editorial. All authors read and approved the final manuscript.
Ethics approval and consent to participate
Not applicable
Consent for publication
Not applicable
Competing interests
The authors declare that they have no competing interests.
Publisher’s Note
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
References
- 1.Saylor D, Steiner TJ. The global burden of headache. Semin Neurol. 2018;38(2):182–190. doi: 10.1055/s-0038-1647245. [DOI] [PubMed] [Google Scholar]
- 2.Martelletti P. Migraine disability complicated by medication overuse. Eur J Neurol. 2018;25(10):1193–1194. doi: 10.1111/ene.13736. [DOI] [PubMed] [Google Scholar]
- 3.Parikh SK, Young WB. Migraine: stigma in society. Curr Pain Headache Rep. 2019;23(1):8. doi: 10.1007/s11916-019-0743-7. [DOI] [PubMed] [Google Scholar]
- 4.D'Amico D, Sansone E, Grazzi L, Giovannetti AM, Leonardi M, Schiavolin S, Raggi A. Multimorbidity in patients with chronic migraine and medication overuse headache. Acta Neurol Scand. 2018;138(6):515–522. doi: 10.1111/ane.13014. [DOI] [PubMed] [Google Scholar]
- 5.Nyholt DR, Borsook D, Griffiths LR. Migrainomics - identifying brain and genetic markers of migraine. Nat Rev Neurol. 2017;13(12):725–741. doi: 10.1038/nrneurol.2017.151. [DOI] [PubMed] [Google Scholar]
- 6.Lionetto L, Gentile G, Bellei E, Capi M, Sabato D, Marsibilio F, Simmaco M, Pini LA, Martelletti P. The omics in migraine. J Headache Pain. 2013;14:55. doi: 10.1186/1129-2377-14-55. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 7.European Headache Federation School of Advanced Studies (EHF-SAS). https://ehf-org.org/aims-and-scope/. Accessed 29 Apr 2019
- 8.Master in Headache Medicine, Sapienza University of Rome. https://web.uniroma1.it/masterheadache/. (viewed 18 Feb 2019)
- 9.Master of Headache Disorders, University of Copenhagen. https://mhd.ku.dk (viewed 18 Feb 2019)
- 10.Kramers C, Janssen BJ, Knol W, Hessel MHM, Mulder WM, Dumont G, van den Brink AM, Tichelaar J. A licence to prescribe. Br J Clin Pharmacol. 2017;83(8):1860–1861. doi: 10.1111/bcp.13257. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 11.Edvinsson L (2019) Role of CGRP in migraine. Handb Exp Pharmacol. 10.1007/164_2018_201 [DOI] [PubMed]
- 12.Ashina H, Schytz HW, Ashina M (2018) CGRP in human models of migraine. Handb Exp Pharmacol. 10.1007/164_2018_128. [DOI] [PubMed]
- 13.Pomes LM, Gentile G, Simmaco M, Borro M, Martelletti P. Tailoring treatment in Polymorbid migraine patients through personalized medicine. CNS Drugs. 2018;32(6):559–565. doi: 10.1007/s40263-018-0532-6. [DOI] [PubMed] [Google Scholar]
- 14.Capi M, Gentile G, Lionetto L, Salerno G, Cipolla F, Curto M, Borro M, Martelletti P. Pharmacogenetic considerations for migraine therapies. Expert Opin Drug Metab Toxicol. 2018;14(11):1161–1167. doi: 10.1080/17425255.2018.1541452. [DOI] [PubMed] [Google Scholar]
Associated Data
This section collects any data citations, data availability statements, or supplementary materials included in this article.
Data Availability Statement
Not applicable